Natera

Youtube Subscribe

Open: 51.37 Close: 52.6 Change: 1.23

Are you looking for information about Natera? We programmed an AI to summarize it for you.

Are looking for the most relevant information about Natera? Investor spend a lot of time searching for information to make investment decisions in Natera. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Natera are: price, Natera, share, health, test, Nateras, Friday, and the most common words in the summary are: natera, stock, market, test, price, news, health, . One of the sentences in the summary was: CEO Steven Leonard Chapman sold 2,605 shares of Natera stock in a transaction dated …

Concept Map

Semantic Network

Stock Summary

Natera, Inc. develops and commercializes molecular testing services worldwide. Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies, is a non invasive prenatal.

Today's Summary

28 analysts offering price forecasts for Nater a median target of 74.00. CEO Steven Leonard Chapman sold 2,605 shares of Natera stock in a transaction dated Wednesday, June 28th.

Today's News

On Friday 08/18/2023 the closing price of the Natera Inc share was $52.60 on NAS. Compared to the opening price on Friday. of $53.39, this is a drop of 1.50%. The 28 analysts offering price forecasts for Nater a median target of 74.00. Natera is a global leader in cell-free DNA testing dedicated to oncology, womens health, and organ health. The company reported revenues from around 594,900 tests in the second quarter of 2023, marking a 29.0% increase compared to the same period in 2022. Natera is capitalizing on its innovative genetic tests, driving growth across various medical fields, especially in womens health, oncology, and organ health. The diagnostic sector is rapidly evolving, and while Nateras leading-edge cfDNA technology places them ahead. nateras prospera™ lung transplant assessment test granted medicare coverage. Nateras Prospera™ Lung Transplant Assessment Test granted Medicare coverage. Natera (NTRA) reported earnings of -$0.97 per share, beating the Zacks Consensus Estimate of $-1.09 per share. The average price target for NaterA is $70.00, which is 33.08% higher than the current price. The beta is 1.17, so Nateras price volatility has been higher than market average. CEO Steven Leonard Chapman sold 2,605 shares of Natera stock in a transaction dated Wednesday, June 28th. CEO Jonathan Sheena sold 5,000 shares of the business on Wednesday, August 2nd. Grabar Law Office is investigating potential claims on behalf of Natera, Inc. - August 12, 2023. Grabar law office investigates claims on. behalf of shareholders of natera inc. (ntra) - consensus buy rating and 34.8% upside potential.

Stock Profile

"Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas."

Keywords

The game is changing. There is a new strategy to evaluate Natera fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Natera are: price, Natera, share, health, test, Nateras, Friday, and the most common words in the summary are: natera, stock, market, test, price, news, health, . One of the sentences in the summary was: CEO Steven Leonard Chapman sold 2,605 shares of Natera stock in a transaction dated Wednesday, June 28th.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #natera #stock #market #test #price #news #health.

Read more →

Youtube Subscribe

---